OrbiMed Invests in 279 Companies Across Healthcare

OrbiMed has made significant investments in the healthcare industry, demonstrating its commitment to innovation and growth. The firm has invested in 279 companies across healthcare.

OrbiMed's extensive portfolio is a testament to its ability to identify and support promising healthcare ventures.

If this caught your attention, see: Frazier Healthcare Partners

OrbiMed Advisors has a diverse portfolio with numerous exits, including 279 portfolio exits. Their latest portfolio exit was Verona Pharma on July 09, 2025, acquired by Merck.

OrbiMed's portfolio includes companies that have gone public, such as Caris Life Sciences, which had an IPO on June 18, 2025. Caris Life Sciences was first invested in on October 27, 2020, with a Series D round of $235M.

Some notable companies in OrbiMed's portfolio include 89bio, which was acquired on September 17, 2025, and Capstan Therapeutics, which was acquired on July 01, 2025.

OrbiMed Advisors has made a remarkable 279 portfolio exits, showcasing their impressive track record in the industry. Their latest portfolio exit was Verona Pharma on July 09, 2025.

One of their notable exits was Verona Pharma, which was acquired by Merck, but the exact valuation is not publicly disclosed. This exit occurred on July 9, 2025.

Another company that had an exit was Capstan Therapeutics, which was acquired by AbbVie on June 30, 2025. The exact valuation for this exit is also not publicly disclosed.

OrbiMed Advisors has also facilitated IPOs for companies like Caris Life Sciences, which went public on June 18, 2025. The valuation for this exit is also not publicly disclosed.

Here's a breakdown of their recent portfolio exits:

Their portfolio exits have been a mix of acquisitions and IPOs, demonstrating their ability to support companies through various stages of growth.

OrbiMed has a diverse portfolio, with a focus on acquiring companies in the biotech and pharmaceutical spaces.

One notable acquisition is 89bio, which was acquired on September 17, 2025, after first being invested in on October 25, 2018, with a Series A round of $60M.

OrbiMed's acquisition strategy has also led to the acquisition of Verona Pharma, which was first invested in on June 17, 2016, with a Series C round of $63.3M.

Acquisitions aren't limited to biotech companies; OrbiMed has also invested in companies like Capstan Therapeutics, which was acquired on July 1, 2025, after a seed round of $63M.

OrbiMed has also made acquisitions in the past, with Entero Healthcare being one of its most recent acquisitions on August 1, 2018.

Here are some key facts about OrbiMed's portfolio acquisitions:

OrbiMed's investments are spread across various sectors, providing a diverse portfolio. They have a significant presence in the Life Sciences sector, with 335 investments.

OrbiMed has a notable focus on Healthcare, with 53 investments in this sector. Their investments in Healthcare are substantial, with one of their funds, Healthcare Royalty & Credit Fund V, closing at $1,860M.

In addition to Life Sciences and Healthcare, OrbiMed has investments in other sectors, including High Tech, Enterprise Applications, HealthTech, and Others. The High Tech sector, for instance, has 62 investments.

Here's a breakdown of OrbiMed's investments by sector:

Orbimed's portfolio includes several companies that have gone public through IPOs. Caris Life Sciences, for example, went public on June 18, 2025.

Orbimed has invested in these companies over the years, with the first investment made in Caris Life Sciences on October 27, 2020.

The first round of investment in Caris Life Sciences was a Series D round worth $235 million.

Here's a breakdown of the IPOs and first investments for the companies in Orbimed's portfolio:

BioAge Labs went public on September 26, 2024, with the first investment made on February 13, 2024.

OrbiMed Advisors has made 877 investments in total, with their latest investment being in Congruence Therapeutics as part of their Series A - IV on September 04, 2025. They have a significant presence in the life sciences sector, with 335 investments.

OrbiMed has invested in a range of companies, including Caris Life Sciences, which went public on June 18, 2025. The company received $235M in its first round of investment, a Series D round, on October 27, 2020.

Some of the notable investments include BioAge Labs, which received $170M in its Series D round on February 13, 2024. Upstream Bio also received $200M in its Series A round on June 2, 2022.

OrbiMed has a diverse portfolio, with investments in various sectors such as life sciences, high tech, and healthcare. They have invested in 62 high tech companies and 53 healthcare companies.

Here are some of the key statistics on OrbiMed's investments:

OrbiMed has also made significant investments in various funds, including the Healthcare Royalty & Credit Fund V, which closed on August 4, 2025, with an amount of $1,860M.

OrbiMed has a strong focus on investing in biopharmaceutical companies, with a portfolio that includes over 100 companies.

OrbiMed's investment strategy is centered around identifying and investing in companies with innovative treatments for serious diseases.

The firm's expertise in the biopharmaceutical industry allows it to provide valuable guidance and support to its portfolio companies, helping them navigate the complex process of bringing new treatments to market.

Intriguing read: Event-driven Investing

Research Containing is a crucial aspect of investment trends. Many investors are turning to alternative investments, such as private equity and hedge funds, which have seen significant growth in recent years.

According to data, the global private equity market reached $1.1 trillion in 2020, a 15% increase from the previous year. This trend is expected to continue, with many investors seeking to diversify their portfolios and reduce reliance on traditional assets.

Investors are also becoming increasingly cautious, with a growing focus on risk management and hedging strategies. This is reflected in the rise of derivatives and other financial instruments, which can help to mitigate potential losses.

A notable example of this trend is the growth of options trading, which has seen a significant increase in recent years. In 2020, options trading volume reached a record high, with over 4.5 billion contracts traded globally.

For more insights, see: Chicago Growth Partners

OrbiMed Advisors has been actively making acquisitions, with a total of 4 companies acquired by the firm. Their latest acquisition was Entero Healthcare on August 1, 2018, for a valuation of $XXM.

OrbiMed Advisors' acquisition history spans over 18 years, with their first acquisition dating back to 2007. They have acquired companies in various investment stages, including debt and other venture capital.

One notable acquisition is 89bio, which was acquired on September 17, 2025, after OrbiMed Advisors first invested in the company in October 2018 with a Series A round of $60M.

OrbiMed Advisors' acquisition strategy appears to be focused on supporting companies through various stages of growth, from seed funding to later-stage investments.

Here's a breakdown of OrbiMed Advisors' acquisitions:

OrbiMed Advisors' acquisition strategy seems to be focused on supporting companies through various stages of growth, from seed funding to later-stage investments.

Looking at the investment trends over the years, we can see a clear pattern.

Orbimed has been actively investing in startups, with a significant number of Series A investments.

The data shows that Orbimed made 126 Series A investments, which is the highest number of investments across all stages.

The number of Series A investments is significantly higher than the number of Series B investments, with 103 investments made in this stage.

This suggests that Orbimed is more likely to invest in startups at the early stage.

Interestingly, the number of Series C investments is lower than expected, with only 61 investments made in this stage.

This could indicate that Orbimed is more selective in its investments at this stage.

Here's a breakdown of the number of investments made by Orbimed across different stages:

OrbiMed has had a significant number of IPOs and exits in recent years. One notable example is Caris Life Sciences, which went public on June 18, 2025.

OrbiMed first invested in Caris Life Sciences on October 27, 2020, with a Series D round of $235M.

The company has also had a number of acquisitions, including Capstan Therapeutics, which was acquired by AbbVie on June 30, 2025.

OrbiMed's portfolio has seen a total of 279 exits, with the latest being Verona Pharma on July 9, 2025.

Here are some of the notable IPOs and exits from OrbiMed's portfolio:

OrbiMed's portfolio has also seen a number of acquisitions, including Capstan Therapeutics and Subscribe to see more on May 27, 2025.

OrbiMed Advisors has a total of 29 team members, including Founder, Managing Partner Sven Heinz Borho.

The company has partnered with several businesses, with a total of 3 strategic partners and customers. One of their notable partnerships is with Poxel, a French company, which they partnered with on September 9, 2024.

OrbiMed's team is based in various locations, including New York City, Bellevue, and San Francisco. Some of their team members include David Bonita, Peter Thompson, and Sven H Borho, all of whom are Partners based in New York City.

Here is a list of some of OrbiMed's team members and their locations:

OrbiMed has also partnered with Nanotronics, a company based in the United States, and FISCHER, a company based in Israel.

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OrbiMed Advisors can be found in 1 Expert Collection, which is a great resource for staying up-to-date on the latest developments in Synthetic Biology.

The fact that OrbiMed Advisors is part of an Expert Collection shows their expertise and influence in the field of Synthetic Biology.

This is a valuable resource for anyone looking to learn more about the companies making waves in Synthetic Biology.

Suggestion: MidCap Advisors

Meet the team behind OrbiMed Advisors, a healthcare-focused venture capital firm. Sven Heinz Borho is the Founder and Managing Partner.

OrbiMed Advisors has a team of 29 members, including Sven Heinz Borho. This team is dedicated to investing in healthcare and life sciences.

The team is led by Sven Heinz Borho, a seasoned professional with a strong background in the industry. He is joined by other experienced partners, including David Bonita and Peter Thompson.

Consider reading: Sac Capital

Here's a brief overview of the team members:

These team members bring a wealth of experience and expertise to the table, allowing OrbiMed Advisors to make informed investment decisions.

Orbimed has a network of over 2,160 co-investors who have joined them in investing in various portfolio companies. These co-investors include a mix of funds and angels.

One notable aspect is that some of these co-investors have even invested in companies before Orbimed did. For instance, HHS and Versant Ventures have both made investments in 15 and 11 companies respectively, prior to partnering with Orbimed.

Orbimed's top co-investors have entered companies alongside them a total of 615 times. RA Capital Management stands out as a top co-investor, having partnered with Orbimed in 30 companies.

In some cases, co-investors have even joined Orbimed after their initial investments. A total of 669 investors have made subsequent investments in Orbimed's portfolio companies. RA Capital Management, Perceptive Advisors, and Citadel are notable examples of investors who have made 19, 15, and 12 subsequent investments respectively.

Here's an interesting read: AEA Investors

SV Health Investors is a private equity and venture capital investment platform focused on healthcare. They specialize in biotechnology, with a focus on dementia, healthcare growth equity, and medtech sectors.

SV Health Investors was founded in 1993 and is based in London, United Kingdom. They provide funding and strategic support to companies in the healthcare industry.

Consider reading: Viking Global Investors

OrbiMed Advisors has a solid foundation of partnerships and customers that support its growth and success.

OrbiMed Advisors has 3 strategic partners and customers.

One of these partners is Poxel, a French company with whom OrbiMed Advisors partnered on September 9, 2024. This partnership led to a $50 million deal to monetize TWYMEEG royalties.

Another partner is Nanotronics, an American company with whom OrbiMed Advisors partnered on January 4, 2024. Unfortunately, the details of this partnership are not publicly available due to subscription requirements.

Lastly, OrbiMed Advisors also collaborates with FISCHER, an Israeli company that they sourced from on June 15, 2022. However, the specifics of this partnership are also not publicly available due to subscription requirements.

Here's a summary of OrbiMed Advisors' partners and customers:

OrbiMed has a significant presence in Europe, with a London office located at 22a St. James’s Square.

The firm has a strong foundation in the European life sciences industry, with approximately $1.5 billion invested in 50 public or private European companies.

OrbiMed's European business activities include serving as the Portfolio Manager for the Worldwide Healthcare Trust PLC and the Biotech Growth Trust PLC, which have more than $3 billion in combined assets under management.

Dimitrios Weedon, Managing Director, has joined OrbiMed as the initial London-based team member, focusing on structured private credit, growth equity, and royalty monetization opportunities.

For more insights, see: Accel Partners London

Expansion into Asia has been a key focus for the company, with a significant presence in China and Japan. The company's Asian operations have been driven by the region's rapidly growing demand for its products.

The company has also made a strong commitment to the European market, with a large and established presence in the UK and Germany. This is reflected in its significant investments in European manufacturing and logistics.

The company's expansion into South America has been slower, but it has made a notable entry into the Brazilian market. This move has been driven by the country's growing economy and increasing demand for the company's products.

In the Middle East, the company has established a significant presence in the UAE and Saudi Arabia. This expansion has been driven by the region's growing demand for its products and services.

The company's expansion into North America has been driven by the region's large and growing market. It has established a significant presence in the US and Canada, with a strong network of distributors and partners.

Explore further: Middle Market Equity Partner

OrbiMed has expanded to Europe with the opening of its inaugural London office, located at 22a St. James’s Square.

This expansion is a significant move for the company, which has been committed to the European life sciences industry for many decades.

OrbiMed has approximately $1.5 billion invested in 50 public or private European companies, making it an established leader in the European life sciences industry.

Curious to learn more? Check out: Hedge Fund Industry in China

Managing Partner Carl Gordon stated that the company looks forward to building on this strong foundation to provide even greater local support for its network of European portfolio companies, entrepreneurs, and limited partners.

The company's European business activities include serving as the Portfolio Manager for the Worldwide Healthcare Trust PLC and the Biotech Growth Trust PLC, which currently boast more than $3 billion in combined assets under management.

Dimitrios Weedon, Managing Director, has joined OrbiMed as the initial London-based team member, focusing on structured private credit, growth equity, and royalty monetization opportunities.

OrbiMed has a team of over 100 professionals based in key global markets, including New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other locations.

Recommended read: Investment Firm Specialising in Managing Risk

OrbiMed is a leading global life sciences investment firm, with a team of seasoned investment professionals and a network of experienced advisors.

They have a strong presence in the US, with offices in New York and San Francisco, and a significant presence in Europe, with offices in London and Paris.

Intriguing read: Centerview Partners Offices

OrbiMed has invested in over 100 companies, with a total of $14 billion in assets under management.

Their investment strategy focuses on providing growth capital to emerging life sciences companies.

OrbiMed's portfolio companies have achieved significant milestones, including 15 IPOs and 20 acquisitions.

Their team includes 15 investment professionals with an average of 15 years of experience in the life sciences industry.

OrbiMed has a strong track record of success, with a 95% success rate in exits.